FSD Pharma Inc.
HUGE · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1 | $0 | -$0 | -$0 |
| G&A Expenses | $2 | $2 | $2 | $3 |
| SG&A Expenses | $2 | $2 | $2 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $2 |
| Operating Expenses | $3 | $2 | $2 | $3 |
| Operating Income | -$3 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $2 |
| Pre-Tax Income | -$3 | -$2 | -$2 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$3 | -$2 | -$2 | -$1 |
| % Margin | – | – | – | – |
| EPS | -0.049 | -0.031 | -0.043 | -0.029 |
| % Growth | -55.4% | 27.6% | -49.1% | – |
| EPS Diluted | -0.079 | -0.048 | -0.043 | -0.029 |
| Weighted Avg Shares Out | 64 | 61 | 39 | 39 |
| Weighted Avg Shares Out Dil | 40 | 40 | 39 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$3 | -$2 | -$2 | -$3 |
| % Margin | – | – | – | – |